This message communicates the pharmacy or treatment application's encoding of the pharmacy/treatment order ,OMP, message. It may be sent as an unsolicited message to report on either a single order or multiple pharmacy/treatment orders for a patient.
The RDE/RRE message pair can also be used to communicate a refill authorization request; however, a specific trigger event has been assigned. See section 4A.3.13 "RDE - Pharmacy/Treatment Refill Authorization Request Message (Event O25)." As a site-specific variant, the original order segments (RXO, RXRs, associated RXCs, and any NTEs) may be sent optionally (for comparison).
The event O11 represents an encoding of an order. To communicate explicit dispense requests, which are different event types, the RDE^O11/RRE^O12 message pair is also used, but the event O49 is preferred. See section 4A.3.23 "RDE - Pharmacy/Treatment Dispense Request Message (Event O49)." As a site-specific variant, the original order segments (RXO, RXRs, associated RXCs, and any NTEs) may be sent optionally (for comparison).
Segment | Cardinality | Implement | Status |
---|---|---|---|
RDE^O11^RDE_O11 | |||
MSH Message Header |
[1..1] | SHALL | |
ARV Access Restriction |
|||
SFT Software Segment |
|||
UAC User Authentication Credential Segment |
[0..1] | ||
NTE Notes and Comments |
|||
PATIENT | [0..1] | ||
PID Patient Identification |
[1..1] | SHALL | |
PD1 Patient Additional Demographic |
[0..1] | ||
PRT Participation Information |
|||
NTE Notes and Comments |
|||
ARV Access Restriction |
B | ||
PATIENT_VISIT | [0..1] | ||
PV1 Patient Visit |
[1..1] | SHALL | |
PV2 Patient Visit - Additional Information |
[0..1] | ||
PRT Participation Information |
|||
ARV Access Restriction |
B | ||
INSURANCE | |||
IN1 Insurance |
[1..1] | SHALL | |
IN2 Insurance Additional Information |
[0..1] | ||
IN3 Insurance Additional Information, Certification |
[0..1] | ||
GT1 Guarantor |
[0..1] | ||
AL1 Patient Allergy Information |
|||
ORDER | [1..*] | SHALL | |
ORC Common Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
TIMING | |||
TQ1 Timing/Quantity |
[1..1] | SHALL | |
TQ2 Timing/Quantity Relationship |
|||
ORDER_DETAIL | [0..1] | ||
RXO Pharmacy/Treatment Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
RXR Pharmacy/Treatment Route |
[1..*] | SHALL | |
COMPONENT | |||
RXC Pharmacy/Treatment Component Order |
[1..1] | SHALL | |
NTE Notes and Comments |
|||
RXE Pharmacy/Treatment Encoded Order |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
TIMING_ENCODED | [1..*] | SHALL | |
TQ1 Timing/Quantity |
[1..1] | SHALL | |
TQ2 Timing/Quantity Relationship |
|||
PHARMACY_TREATMENT_INFUSION_ORDER | |||
RXV Pharmacy/Treatment Infusion |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
TIMING_ENCODED | [1..*] | SHALL | |
TQ1 Timing/Quantity |
[1..1] | SHALL | |
TQ2 Timing/Quantity Relationship |
|||
RXR Pharmacy/Treatment Route |
[1..*] | SHALL | |
RXC Pharmacy/Treatment Component Order |
|||
CDO Cumulative Dosage |
|||
OBSERVATION | |||
OBX Observation/Result |
[1..1] | SHALL | |
PRT Participation Information |
|||
NTE Notes and Comments |
|||
FT1 Financial Transaction |
|||
BLG Billing |
[0..1] | ||
CTI Clinical Trial Identification |
MSH-15 | MSH-16 | Immediate ACK | Application Ack |
---|---|---|---|
Blank | Blank | - | RRE^O26^RRE_O26 |
Blank | Blank | - | RRE^O12^RRE_O12 orOSU^O52^OSU_O52 |
NE | NE | - | - |
NE | NE | - | - |
NE | AL, SU, ER | - | RRE^O26^RRE_O26 |
NE | AL, SU, ER | - | RRE^O12^RRE_O12 orOSU^O52^OSU_O52 |
AL, SU, ER | AL, SU, ER | ACK^O25^ACK | RRE^O26^RRE_O26 |
AL, SU, ER | AL, SU, ER | ACK^O11^ACK | RRE^O12^RRE_O12 orOSU^O52^OSU_O52 |